{"title":"默克公司与辉瑞公司和遵守治疗公司合作，旨在加强糖尿病产品组合","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I5.1938","DOIUrl":null,"url":null,"abstract":"Merck & Co. has formed a collaboration with Abide Therapeutics, a spin-out from The Scripps Research Institute, to discover, develop and commercialise small molecule therapies for the treatment of type 2 diabetes by targeting enzymes of the serine hydrolase class. Serine hydrolases represent one of the largest known enzyme families but are mostly under-explored as drug targets. The deal comes only days after Merck partnered with Pfizer to co-develop and co-commercialise ertugliflozin (PF-04971729), a sodium glucose co-transporter 2 (SGLT-2) inhibitor that is expected to enter Phase III development for type 2 diabetes later in 2013.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"58 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I5.1938\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Merck & Co. has formed a collaboration with Abide Therapeutics, a spin-out from The Scripps Research Institute, to discover, develop and commercialise small molecule therapies for the treatment of type 2 diabetes by targeting enzymes of the serine hydrolase class. Serine hydrolases represent one of the largest known enzyme families but are mostly under-explored as drug targets. The deal comes only days after Merck partnered with Pfizer to co-develop and co-commercialise ertugliflozin (PF-04971729), a sodium glucose co-transporter 2 (SGLT-2) inhibitor that is expected to enter Phase III development for type 2 diabetes later in 2013.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"58 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I5.1938\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I5.1938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
默克公司(Merck & Co.)与Scripps研究所(The Scripps Research Institute)的衍生公司Abide Therapeutics合作，发现、开发和商业化针对丝氨酸水解酶类的小分子疗法，用于治疗2型糖尿病。丝氨酸水解酶是已知的最大的酶家族之一，但作为药物靶点尚未得到充分的研究。就在几天前，默克与辉瑞合作，共同开发和共同商业化ertuglliflozin (f -04971729)，这是一种钠葡萄糖共转运蛋白2 (SGLT-2)抑制剂，预计将于2013年晚些时候进入2型糖尿病的III期开发。
Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio
Merck & Co. has formed a collaboration with Abide Therapeutics, a spin-out from The Scripps Research Institute, to discover, develop and commercialise small molecule therapies for the treatment of type 2 diabetes by targeting enzymes of the serine hydrolase class. Serine hydrolases represent one of the largest known enzyme families but are mostly under-explored as drug targets. The deal comes only days after Merck partnered with Pfizer to co-develop and co-commercialise ertugliflozin (PF-04971729), a sodium glucose co-transporter 2 (SGLT-2) inhibitor that is expected to enter Phase III development for type 2 diabetes later in 2013.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
